Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.
about
Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@en
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@nl
type
label
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@en
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@nl
prefLabel
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@en
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@nl
P2860
P356
P1476
Comment: Management of De Novo ...... ne Kinase Inhibitor Dasatinib.
@en
P2093
Ilhan Dolasik
P2860
P304
P356
10.1177/1060028015627663
P407
P577
2016-02-02T00:00:00Z